CN1322197A - 具有抗惊厥作用的新的4－氨基－1－芳基吡啶－2－酮类化合物及其制备方法 - Google Patents

具有抗惊厥作用的新的4－氨基－1－芳基吡啶－2－酮类化合物及其制备方法 Download PDF

Info

Publication number
CN1322197A
CN1322197A CN99811849A CN99811849A CN1322197A CN 1322197 A CN1322197 A CN 1322197A CN 99811849 A CN99811849 A CN 99811849A CN 99811849 A CN99811849 A CN 99811849A CN 1322197 A CN1322197 A CN 1322197A
Authority
CN
China
Prior art keywords
amino
ones
pyridin
compound
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99811849A
Other languages
English (en)
Inventor
H·－J·兰考
K·翁维尔菲尔斯
T·阿诺
R·巴特施
A·罗斯托克
V·格拉尼克
S·格利兹克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AWD Pharma GmbH and Co KG
Original Assignee
Arzneimittelwerk Dresden GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arzneimittelwerk Dresden GmbH filed Critical Arzneimittelwerk Dresden GmbH
Publication of CN1322197A publication Critical patent/CN1322197A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Abstract

本发明涉及式(1)新的4－氨基－1－芳基吡啶－2－酮类化合物,其中n=0、1、2、3、4、5,X是氢、C1－C4－烷基、C1－C4－烷氧基、三氟甲基、三氟甲氧基或卤素,且A是氨基、C1－C4－烷基氨基、C1－C4－二烷基氨基、吗啉代、哌啶子基或吡咯烷子基。本发明还涉及制备式(1)化合物的方法及其作为药物、尤其是治疗不同类型癫痫的药物的应用。

Description

具有抗惊厥作用的新的4-氨基-1-芳基吡啶 -2-酮类化合物及其制备方法
本发明涉及新的4-氨基-1-芳基吡啶-2-酮类化合物，其制备方法，及其作为药物的应用，尤其是作为治疗不同类型癫痫的药物的应用。
依据现有技术，通过将4-羟基-1H-吡啶-2-酮类与胺衍生物反应可制得在1-位未被取代的4-氨基吡啶-2-酮类[Synthesis；9(1984)；765-766]。在1-位进一步芳基化来制得通式1化合物是不可能的，因此不能依据该方法制得本发明化合物。
另一方法描述了1-芳基-4-氨基-3-氰基-5-烷氧基羰基吡啶-2-酮类的合成[Chem.Ber.114(11)；(1981)；3471-3484]。因为在该方法中使用了二聚氰基乙酸酯作为原料，在该吡啶-2-酮的3-位和5-位上需要取代基，所以同样不能依据该方法制得本发明化合物。
现有技术中没有描述过通式1所示4-氨基-1-芳基吡啶-2-酮类。
大量具有抗惊厥活性的化合物是已知的。然而，仍然非常需要新的抗惊厥剂，这是因为即使在现在也不是所有癫痫病症都能得到令人满意的治疗。
本发明的目的是获得具有良好药理特性的、可尤其是作为具有抗惊厥活性的药物使用的新化合物。
依据本发明，这些新化合物是通式1所示4-氨基-1-芳基吡啶-2-酮类化合物：
Figure A9981184900051
n＝0，1，2，3，4，5
其中
X＝氢、C1-C4-烷基、C1-C4-烷氧基、三氟甲基、三氟甲氧基或卤素，且
A＝氨基、C1-C4-烷基氨基、C1-C4-二烷基氨基、吗啉代、哌啶子基或吡咯烷子基(Pyrrolidino)。
可提及的通式1化合物的实例有：
4-氨基-1-苯基吡啶-2-酮
4-氨基-1-(2-氯苯基)吡啶-2-酮
4-氨基-1-(4-氯苯基)吡啶-2-酮
4-氨基-1-(2-甲基苯基)吡啶-2-酮
4-氨基-1-(3-甲基苯基)吡啶-2-酮
4-氨基-1-(4-甲基苯基)吡啶-2-酮
4-氨基-1-(4-甲氧基苯基)吡啶-2-酮
4-氨基-1-(4-三氟甲氧基苯基)吡啶-2-酮
4-氨基-1-(2，6-二氯苯基)吡啶-2-酮
4-氨基-1-(2-氟苯基)吡啶-2-酮
4-氨基-1-(4-氟苯基)吡啶-2-酮
4-氨基-1-(2，6-二氟苯基)吡啶-2-酮
4-氨基-1-(2-氯-4-氟苯基)吡啶-2-酮
1-(2-氯苯基)-4-二甲基氨基吡啶-2-酮
1-(2-氯苯基)-4-(4-吗啉代)吡啶-2-酮。
依据本发明，通式1化合物可依据新方法通过将通式2化合物反应来制得，n＝0，1，2，3，4，5
其中
X＝氢、C1-C4-烷基、C1-C4-烷氧基、三氟甲基、三氟甲氧基或卤素，且
R＝C1-C4-烷基。
通式2嘧啶衍生物可通过简单方法合成(Chem.Heterocycl.Compd.；24(8)；(1988)；914-919；Khim.Geterotsikl.Soedin.；8；(1988)；1109-1114)。
通式1化合物可通过两个步骤制得，将通式2嘧啶衍生物在碱性介质中、优选在5-50％氢氧化钠溶液中于50℃-150℃加热0.1-10小时、优选1小时。然后将该混合物与强酸、优选50-98％硫酸在100℃-200℃加热10-30分钟。可依据已知方法将该伯氨基一烷基化或二烷基化。优选用硫酸二甲酯、碘甲烷、1，4-二溴丁烷、1，5-二溴戊烷或二(2-氯乙基)醚进行烷基化。
本发明通式1化合物适于制备药物组合物。这些药物组合物含有至少一种本发明通式1化合物。可使用常规药物赋形剂和辅料来制备药物制剂。
本发明药物可例如非胃肠道给药(例如静脉内给药、肌内给药、皮下给药)或者口服给药。
可依据制药领域中的常规已知方法制备合适的给药剂型。
对本发明化合物进行的试验表明它们具有强的抗惊厥作用。
依据国际惯例标准(Pharmac.Weekblad.Sc.Ed.14，132(1992)和Antiepileptic Drugs，Third Ed.，Raven Press，New York 1989)，对小鼠腹膜内给药或对大鼠口服给药后，测定本发明化合物的体内抗惊厥作用。
例如，对于施用于大鼠的化合物4-氨基-1-苯基吡啶-2-酮(实施例1)，对于最大电休克所测定的ED50(p.o.)为3.1mg/kg，对于rotorod所测定的ED50＝200mg/kg。与其相比，已知的抗癫痫剂仅在最大电休克模型中在相当高的剂量下起反应，或者具有相当强的不利的(神经毒性)副作用。
表1
  实施例化合物     X     A  试验1)    剂量2)    作用3)
    1 H NH2  MESRotorod     10100     3040
    2 4-Cl NH2  MESRotorod     100300     300
    3 4-CH3 NH2  MESRotorod     3030     1000
    4 2-CH3 NH2  MESRotorod     30100     700
    5 4-CH3-O NH2  MESRotorod     30300     300
    6 4-CF3-O NH2  MESRotorod     100300     700
    7 3-CH3 NH2  MESRotorod     3030     1000
    8 3-Cl NH2  MESRotorod     100100     5015
    9 2-Cl，6-Cl NH2  MESRotorod     100300     700
    10 4-F NH2  MESRotorod     10100     300
    11 2-Cl，3-Cl NH2  MESRotorod     30100     3030
    12 2-F NH2  MESRotorod     30100     10015
    13 2-Cl NH2  MESRotorod     1030     7015
    14 2-F，6-F NH2  MESRotorod     3030     1000
    15 2-Cl，4-F NH2  MESRotorod     10100     10030
    16 2-Cl N(CH3)2  MESRotorod     3030     300
    17 2-Cl N(CH2CH2)O  MESRotorod     3030     1000
    比较物
卡马西平  MESRotorod     100100     10060
丙戊酸盐  MESRotorod     100100     100
表1的脚注：
1)小鼠，腹膜内给药；MES＝最大电休克
                    Rotorod＝神经毒性
2)mg/kg
3)保护动物所占的％或者表现出可见神经毒性作用的动物所占的％
结果发现本发明所要求保护的化合物具有抗惊厥活性并具有低的副作用，这使得本发明化合物能用于制备治疗不同类型癫痫的药物。
制备实施例
通过下述实施例来更详细地解释本发明化合物的制备。
这些实施例只是举例性列举，并不是对本发明范围的限制。
制备表1实施例1-15所示式1化合物的一般方法
一般合成方法
将0.05mol通式2嘧啶衍生物在100ml 10％氢氧化钠溶液中加热回流1小时。冷却后，将该反应混合物过滤，用水(每次50ml)将滤器上的残余物洗涤2次。用100ml 75％硫酸处理该固体，并在预热的油浴中加热至180℃。几分钟(依据表2的反应时间)后，将该反应混合物迅速冷却，用200ml水稀释，并用氨水将其碱化。分离出沉淀并重结晶。
制备表1实施例16和17所示式1化合物的一般方法
A  在甲醇钠存在下，用合适的烷化剂例如硫酸二甲酯或二(2-氯乙基)醚将依据上述一般方法制得的4-氨基吡啶-2-酮(实施例1-15)烷基化。将该反应混合物置于水中。分离出沉淀并重结晶。
表2
Figure A9981184900101
  实施例序号 X   A   反应时间(分钟)     重结晶所用溶剂：   m.p.(℃)    产率(％)
    1     H   NH2     15     乙醇   288     67
    2     4-Cl   NH2     15     甲醇   312     71
    3     4-CH3   NH2     15     乙醇   283     38
    4     2-CH3   NH2     30     甲醇   267     31
    5     4-CH3-O   NH2     15     异丙醇   298     21
    6     4-CF3-O   NH2     10     甲醇   296     44
    7     3-CH3   NH2     20     异丙醇   243     40
    8     3-Cl   NH2     15     甲醇   285     62
    9     2-Cl，6-Cl   NH2     20     异丙醇   282     46
    10     4-F   NH2     15     异丙醇   283     58
    11     2-Cl，3-Cl   NH2     15     异丙醇   270     32
    12     2-F   NH2     15     乙醇   270     55
    13     2-Cl   NH2     15     乙醇   259     64
    14     2-F，6-F   NH2     15     异丙醇   216     51
    15     2-Cl，4-F   NH2     20     异丙醇   255     66
    16     2-Cl   N(CH3)2     15     异丙醇   185     68
    17     2-Cl   N(CH2CH2)O     15     异丙醇   183     52

Claims (12)

1.通式1新化合物：
Figure A9981184900021
n＝0，1，2，3，4，5
其中
X＝氢、C1-C4-烷基、C1-C4-烷氧基、三氟甲基、三氟甲氧基或卤素，且
A＝氨基、C1-C4-烷基氨基、C1-C4-二烷基氨基、吗啉代、哌啶子基或吡咯烷子基。
2.权利要求1的化合物：
4-氨基-1-苯基吡啶-2-酮
4-氨基-1-(2-氯苯基)吡啶-2-酮
4-氨基-1-(4-氯苯基)吡啶-2-酮
4-氨基-1-(2-甲基苯基)吡啶-2-酮
4-氨基-1-(3-甲基苯基)吡啶-2-酮
4-氨基-1-(4-甲基苯基)吡啶-2-酮
4-氨基-1-(4-甲氧基苯基)吡啶-2-酮
4-氨基-1-(4-三氟甲氧基苯基)吡啶-2-酮
4-氨基-1-(2，6-二氯苯基)吡啶-2-酮
4-氨基-1-(2-氟苯基)吡啶-2-酮
4-氨基-1-(4-氟苯基)吡啶-2-酮
4-氨基-1-(2，6-二氟苯基)吡啶-2-酮
4-氨基-1-(2-氯-4-氟苯基)吡啶-2-酮
1-(2-氯苯基)-4-二甲基氨基吡啶-2-酮
1-(2-氯苯基)-4-(4-吗啉代)吡啶-2-酮。
3.制备通式1化合物的方法，其特征在于，将通式2化合物
Figure A9981184900031
n＝0，1，2，3，4，5
其中
X＝氢、C1-C4-烷基、C1-C4-烷氧基、三氟甲基、三氟甲氧基或卤素，且
R＝C1-C4-烷基，
在碱性介质中于50C-150℃加热0.1-10小时，然后与强酸在100℃-200℃加热10-30分钟。
4.权利要求3的制备通式1化合物的方法，其特征在于，优选使用5-50％氢氧化钠溶液。
5.权利要求3的制备通式1化合物的方法，其特征在于，加热优选在碱性介质中进行1小时。
6.权利要求3的制备通式1化合物的方法，其特征在于，优选使用50-98％硫酸。
7.制备其中A＝C1-C4-烷基氨基、C1-C4-二烷基氨基、吗啉代、哌啶子基或吡咯烷子基的通式1化合物的方法，其特征在于，将通式2化合物
Figure A9981184900032
n＝0，1，2，3，4，5
其中
X＝氢、C1-C4-烷基、C1-C4-烷氧基、三氟甲基、三氟甲氧基或卤素，且
R＝C1-C4-烷基，
在碱性介质中于50℃-150℃加热0.1-10小时，然后与强酸在100℃-200℃加热10-30分钟，之后在碱性介质中烷基化。
8.权利要求7的制备通式1化合物的方法，其特征在于，优选用硫酸二甲酯、碘甲烷、1，4-二溴丁烷、1，5-二溴戊烷或二(2-氯乙基)醚进行烷基化。
9.药物制剂，其特征在于，所述药物制剂含有至少一种通式1化合物作为活性组分，并且如果适当的话，还含有药物赋形剂和辅料。
10.权利要求9的药物制剂，其特征在于，所述药物制剂含有至少一种权利要求2的化合物作为活性组分。
11.通式1化合物在制备用于治疗不同类型癫痫病症的药物中的应用。
12.权利要求2的化合物在制备用于治疗不同类型癫痫病症的药物中的应用。
CN99811849A 1998-08-07 1999-07-28 具有抗惊厥作用的新的4－氨基－1－芳基吡啶－2－酮类化合物及其制备方法 Pending CN1322197A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19835918A DE19835918A1 (de) 1998-08-07 1998-08-07 Neue antikonvulsiv wirkende 4-Amino-1-aryl-pyridin-2-one und Verfahren zu deren Herstellung
DE19835918.7 1998-08-07

Publications (1)

Publication Number Publication Date
CN1322197A true CN1322197A (zh) 2001-11-14

Family

ID=7876889

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99811849A Pending CN1322197A (zh) 1998-08-07 1999-07-28 具有抗惊厥作用的新的4－氨基－1－芳基吡啶－2－酮类化合物及其制备方法

Country Status (21)

Country Link
US (1) US6071911A (zh)
EP (1) EP1102748A1 (zh)
JP (1) JP2002522420A (zh)
KR (1) KR20010074802A (zh)
CN (1) CN1322197A (zh)
AR (1) AR021186A1 (zh)
AU (1) AU5507499A (zh)
BG (1) BG105196A (zh)
BR (1) BR9912849A (zh)
CA (1) CA2279692C (zh)
DE (1) DE19835918A1 (zh)
HU (1) HUP0103204A3 (zh)
IL (1) IL141200A0 (zh)
NO (1) NO20010575L (zh)
NZ (1) NZ509914A (zh)
PL (1) PL346013A1 (zh)
RU (1) RU2001106634A (zh)
SK (1) SK2002001A3 (zh)
TR (1) TR200100370T2 (zh)
WO (1) WO2000007988A1 (zh)
ZA (1) ZA200100999B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522773A (en) 2000-06-12 2005-06-24 Eisai Co Ltd 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
WO2020124090A1 (en) 2018-12-14 2020-06-18 Eisai R&D Management Co., Ltd. Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118768A (en) * 1975-02-19 1976-10-18 Shigeo Senda Method for preparing 4-amino-2-pyridone derivatives
ATE25078T1 (de) * 1982-10-27 1987-02-15 Degussa 2-amino-3-acylamino-6-benzylamino-pyridinderivate mit anti-epileptischer wirkung.

Also Published As

Publication number Publication date
CA2279692C (en) 2003-10-07
PL346013A1 (en) 2002-01-14
TR200100370T2 (tr) 2001-08-21
US6071911A (en) 2000-06-06
WO2000007988A1 (de) 2000-02-17
ZA200100999B (en) 2001-12-14
AU5507499A (en) 2000-02-28
DE19835918A1 (de) 2000-02-10
NO20010575D0 (no) 2001-02-02
AR021186A1 (es) 2002-07-03
SK2002001A3 (en) 2002-01-07
RU2001106634A (ru) 2004-02-27
NO20010575L (no) 2001-04-04
CA2279692A1 (en) 2000-02-07
KR20010074802A (ko) 2001-08-09
IL141200A0 (en) 2002-02-10
BR9912849A (pt) 2001-05-08
HUP0103204A3 (en) 2002-06-28
BG105196A (en) 2001-12-29
HUP0103204A2 (hu) 2002-04-29
JP2002522420A (ja) 2002-07-23
NZ509914A (en) 2002-11-26
EP1102748A1 (de) 2001-05-30

Similar Documents

Publication Publication Date Title
JP5406827B2 (ja) （チオ）カルバモイル−シクロヘキサン誘導体の代謝物
US3804898A (en) Novel benzcyclobutene derivatives
EP1454901B1 (en) Pharmaceutical compositions comprising tachykinins antagonists and a serotonin reuptake inhibitor.
DE2749950C2 (zh)
DE60317198T2 (de) Proteinkinaseinhibitoren
EP0642513B1 (de) Indolocarbazol-imide und deren verwendung
RU2197493C2 (ru) Производные 5h-тиазол[3,2-а]пиримидина, промежуточные продукты и лекарственное средство
EP0120465B1 (de) Neue N-Phenyl-N'-Cycloalkylalkanoyl-piperazine und Verfahren zu deren Herstellung
CH643817A5 (de) Verfahren zur herstellung von neuen benzamid-derivaten.
CH660484A5 (de) In 1-stellung durch einen heterocyclischen rest substituierte 4-((2,5-pyrrolidindion-1-yl)alkyl)piperazin-verbindungen.
JP2008528674A (ja) 治療効果を有する新規化合物
PT2277865E (pt) Heterociclos de azoto de anel de 6 membros fenil substituídos como inibidores de polimerização de microtúbulos
EP2491017B1 (en) Alpha adrenergic receptor modulators
EP1529041B1 (de) Neue prodrugs von 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(n -2-pyridil-n-2-hydroxycarbonylethyl)-amid, ihre herstellung und ihre verwendung als arzneimittel
EP0775135B1 (de) N-substituierte 3-azabicyclo(3.2.0)heptan-derivate als neuroleptika
DE3620643A1 (de) Thiazole, ihre herstellung und verwendung
CN1322197A (zh) 具有抗惊厥作用的新的4－氨基－1－芳基吡啶－2－酮类化合物及其制备方法
DE3615180C2 (de) Disubstituierte 1,4-Piperazinylderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel
EP0799210A1 (en) Piperazine-2,5-dione derivatives as modulators of multidrug resistance
EP0456133A1 (de) Hydrazone
EP0775113B1 (de) N-substituierte azabicycloheptan-derivate als neuroleptika usw.
CH449632A (de) Verfahren zur Herstellung von cyclischen Diazacycloalkanverbindungen
EP0589903B1 (de) Aminoalkylsubstituierte 5-mercaptothiazole, ihre herstellung und verwendung
DE2246728A1 (de) Neue substituierte aethylendiamine, verfahren zu ihrer herstellung und solche diamine enthaltende arzneipraeparate
JP2005534701A (ja) アミノアルキル置換アリール化合物及びナトリウムチャネルブロッカーとしてのそれらの使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication